Pharmateca
Cure8 research brief
Algorithms for the diagnosis and treatment of ulcerative colitis
Tests and monitoring
CRP
Clinical study
Clinicians
Adult patients
Newly Diagnosed
Ulcerative colitis
Why This Matters
Algorithms guide how UC is diagnosed and monitored (endoscopy, labs, fecal markers, imaging) and when to escalate to surgery or other interventions; that affects surveillance, treatment choices, and complication prevention.
Understanding recommended tests and when they’re used helps patients and clinicians make informed decisions.
Who Should Pay Attention
Clinicians, gastroenterology trainees, adult patients with ulcerative colitis, newly diagnosed patients
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthMetadata only
What To Know
This article is a clinical review titled “Algorithms for the diagnosis and treatment of ulcerative colitis” published in Pharmateca (2026).
It summarizes diagnostic pathways and treatment decision algorithms for ulcerative colitis, referencing endoscopy, biopsy, laboratory markers (CRP), fecal calprotectin, imaging such as intestinal/abdominal ultrasound, and common complications like toxic megacolon and dysplasia.
The paper appears to cite guidelines and prior literature on colonoscopy’s role in monitoring dysplasia/cancer risk and discusses therapeutic options historically used in UC (5-ASA referenced in the bibliography).
The review compiles diagnostic tests and procedures clinicians typically use (colonoscopy with biopsy, sigmoidoscopy, stool testing, blood tests including CRP, fecal calprotectin, and ultrasound) and addresses surgical/endoscopic interventions and complications encountered in UC care.
This is a literature-based algorithmic review rather than a new clinical trial. It may be useful as a reference for clinicians and informed patients seeking an overview of current diagnostic and management pathways for ulcerative colitis.
Keep In Mind
This is a literature-based algorithmic review citing prior guidelines and studies; it does not present new trial results. Use it as an overview and consult professional guidelines and a treating clinician for personal care decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPharmateca
PublisherBionika Media
AuthorsBelous S.S. Belous, Vykova B.A. Vykova
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 13, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Machine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
Effectiveness and Safety of Mirikizumab in Patients With Moderate-to-severe Ulcerative Colitis: a Real-life Retrospective Multicenter Study
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...